abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Cette page n’est pas disponible en Français et est affichée en English

Article

9 Sep 2008

Auteur:
James Mackenzie, Reuters

Malaria campaigners hopeful on drugs pricing deal

Anti-malaria campaigners are confident that a deal can be reached with pharmaceuticals groups to cut the cost of new drugs needed to fight a disease estimated to kill more than 1 million people a year... Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria [said]..."Some firms were complaining that they had produced too much of these medicines. We're hoping an agreement will enable us to regulate the flow better so that everyone benefits."...Novartis and France's Sanofi are among the Western companies that make the drug but the sector has been shaken by the arrival of Chinese and Indian companies like Cipla and IPCA Laboratories.